Figure 5 | Scientific Reports

Figure 5

From: A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer’s disease and tauopathy in mice

Figure 5

HDAC6 dependency of in vivo pharmacodynamics effect of T-518. Absence of HDAC6 expression in the cerebral cortex of HDAC6 KO mice was confirmed by Western blotting (A). T-518 was administered to 27-week-old male WT mice or HDAC6 KO mice at 300 mg/kg, and tubulin acetylation was assessed (B). Full-length gel of (A) is presented in Figure S6. Data was expressed as mean ± SEM and analyzed statistically as a follow: Tukey test (**p < 0.01), n = 5. n.s. not significant.

Back to article page